Target intelligence / Profile preview

Otoconin-90 (OC90)

Target
OC90
Molecular classification
Other (structural matrix protein), phospholipase A2 homolog, glycoprotein
01

Overview

Otoconin-90 (OC90) is a glycoprotein comprising the vast majority of the protein content in otoconia of mammals, which are calcium carbonate crystals crucial for sensing gravity and balance in the vestibular system[1][3][4]. OC90 has two domains homologous to secretory phospholipase A2, contributing to its function in matrix organization and crystal formation, although it lacks enzymatic activity and instead acts structurally to organize and scaffold crystal nucleation and growth[1][3]. It interacts with other matrix proteins like Otolin-1, ensuring proper organization and size of otoconia[4]. OC90 deficiency leads to impaired otoconia biogenesis and severe vestibular dysfunction, as demonstrated in knockout mouse studies[4]. Because OC90 is not an enzyme, receptor, or transporter, it is not considered a conventional pharmacological target. There are no known drugs or compounds that interact directly with OC90 for therapeutic purposes[1][3][4].

Other names
Otoconin-90OC90PLA2LOc90Phospholipase A2 homologotoconin-90phospholipase A2 homolog
02

Mechanism of action

null

03

Biological functions

Organizer of the organic matrix for otoconia genesisScaffold for oriented deposition of calcium carbonate crystals (calcite)Recruiter of other minor otoconial proteins (e.g., Otolin-1)Facilitator of nucleation and inhibitor of crystal growth (in context of biomineralization)
04

Disease associations

Deficient or abnormal OC90 implicated in vertigo, balance deficits, and inner ear disorders related to otoconia formationEssential for proper vestibular function; mutations/deletions cause severe imbalance in mice
05

Interacting drugs

None known; no therapeutic agents are reported to target OC90, as it is a structural protein not generally considered a drug target
06

Biomarkers

OC90 levels or presence may be evaluated as indicators of otoconia integrity or inner ear developmental health

Beyond the preview

Go deeper on Otoconin-90 (OC90).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otoconin-90 (OC90).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call